Australian Prescriber最新文献_第9页

RSV: an update on prevention and management. RSV：预防和管理的最新情况。

IF 3.4

Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.018

David A Foley, Linny K Phuong

{"title":"RSV: an update on prevention and management.","authors":"David A Foley, Linny K Phuong","doi":"10.18773/austprescr.2025.018","DOIUrl":"https://doi.org/10.18773/austprescr.2025.018","url":null,"abstract":"Respiratory syncytial virus (RSV) is a common cause of respiratory tract infections in infants and young children, and adults over 60 years of age. Infants born prematurely, adults aged over 75 years, individuals with medical conditions such as chronic cardiac or respiratory disease, or obesity, and Aboriginal and Torres Strait Islander people are at increased risk of severe RSV disease. As the management of RSV disease is mainly supportive, routine testing for RSV in people with a respiratory illness is not recommended. In high-risk populations and individuals presenting with severe illness, respiratory virus testing should prioritise influenza and COVID-19, as there are specific antiviral drugs for these diseases. Recent approval of RSV vaccines and a new long-acting RSV monoclonal antibody has created opportunities to minimise adverse outcomes associated with RSV infection. Protection against severe RSV disease in infants can be achieved through vaccination of their mother between weeks 28 and 36 of pregnancy, or by administering an RSV monoclonal antibody after delivery. There is currently no RSV vaccine approved for neonates or infants. For older adults, at the time of writing there are 2 approved RSV vaccines available.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"34-39"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Noninvasive prenatal testing: an overview. 无创产前检测：综述。

IF 3.4

Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.019

Alice Poulton, Lisa Hui

{"title":"Noninvasive prenatal testing: an overview.","authors":"Alice Poulton, Lisa Hui","doi":"10.18773/austprescr.2025.019","DOIUrl":"https://doi.org/10.18773/austprescr.2025.019","url":null,"abstract":"Australian health authorities recommend offering prenatal screening for fetal chromosome conditions, also known as aneuploidies (e.g. Down syndrome [trisomy 21]), to all pregnant individuals to support informed decision-making. Noninvasive prenatal testing (NIPT) is one of 3 types of prenatal aneuploidy screening tests available in Australia. NIPT requires a maternal blood test after 10 weeks gestation. Although it doesn't require an ultrasound, a 12- or 13-week ultrasound is recommended as it provides an opportunity for early diagnosis of major structural anomalies. NIPT is not subsidised by Medicare. It is important to take a patient-centred approach when discussing screening options. Patients should be encouraged to consider whether knowing the test result will impact their pregnancy decision-making or preparations. There are two main NIPT approaches: genome-wide and targeted. All currently available NIPT platforms perform well for detecting the common autosomal aneuploidies (trisomy 21, 18 and 13). NIPT has the highest true-positive rate (highest sensitivity) and lowest false-positive rate (highest specificity) among aneuploidy screening methods, however false-positive results can occur. Genetic counselling and confirmatory invasive diagnostic testing are recommended for patients with a high-probability NIPT result, especially if they are considering pregnancy termination.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"47-53"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osilodrostat for Cushing syndrome. 奥西洛司他治疗库欣综合征。

IF 3.4

Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.010

引用次数: 0

The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion. 三联抗栓治疗在房颤和冠状动脉支架置入患者中的作用。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.009

Kate Ziser, Saqib Rahman, Reham Soro, Nazanin Falconer, Danielle Harrop

{"title":"The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion.","authors":"Kate Ziser, Saqib Rahman, Reham Soro, Nazanin Falconer, Danielle Harrop","doi":"10.18773/austprescr.2025.009","DOIUrl":"10.18773/austprescr.2025.009","url":null,"abstract":"Triple antithrombotic therapy or 'triple therapy' describes the combination of 3 oral antithrombotic medications - an anticoagulant drug (warfarin, apixaban, rivaroxaban or dabigatran) and 2 antiplatelet drugs (usually aspirin plus clopidogrel). Most commonly, triple therapy is indicated for patients who require both dual antiplatelet therapy following coronary stent insertion for acute coronary syndrome and long-term anticoagulation for atrial fibrillation. Current evidence supports shorter durations of triple therapy to mitigate bleeding risks without compromising ischaemic protection. Recent guidelines advocate up to 1 week of triple therapy for most patients, extending up to 1 month for those at high ischaemic risk. In practice, the approach to antithrombotic therapy is individualised by the patient's cardiologist, balancing bleeding and ischaemic risks. General practitioners and pharmacists have an important role in supporting patients in their step-down plan to dual therapy with the oral anticoagulant drug and one of the antiplatelet drugs, and then ongoing monotherapy with the oral anticoagulant drug.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 1","pages":"18-22"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy. 马伐卡坦治疗症状性阻塞性肥厚性心肌病。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.006

引用次数: 0

Propranolol overdose following prescription for anxiety. 服用过量心得安治疗焦虑。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.005

Evan Browne, Jacqueline Huber, Bridin Murnion

引用次数: 0

Australian Prescriber: celebrating 50 years of growth and change. 澳大利亚处方：庆祝50年的成长和变化。

IF 3.4